TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36137672
Drug: Abbreviated antiplatelet
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abbreviated antiplatelet therapy (APT) regimen (DAPT stopped and 11 months single APT or 5 months in patients with oral anticoagulants)
Study: 36137672
Drug: Abbreviated antiplatelet
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abbreviated antiplatelet therapy (APT) regimen
Study: 36137672
Drug: Nonabbreviated antiplatelet
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonabbreviated antiplatelet therapy (APT) regimen (DAPT for minimum 3 months)
Study: 33422431
Drug: Traditional medical
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional medical treatment (Control)
Study: 34578811
Drug: 2 g/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/L dipeptide (alanyl‐glutamine)‐electrolytes (AG + E)
Study: 35446628
Drug: ADT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT plus orteronel (300 mg oral twice daily)
Study: 35446628
Drug: ADT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT with bicalutamide (50 mg oral once daily)
Study: 34126270
Drug: LAAO with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAAO with same-day discharge and early cessation of antithrombotic therapy
Study: 35691258
Drug: Pistacia atlantica
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pistacia atlantica subsp. Kurdica herbal capsule for 2 months
Study: 35691258
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule for 2 months
Study: 33722477
Drug: Individualized follitropin
Normalized name: FOLLITROPIN
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Individualized follitropin delta dosing (AMH <15 pmol/l: 12 µg/day; AMH ≥15 pmol/l: 0.10–0.19 µg/kg/day; minimum 6 µg/day; maximum 12 µg/day)
Study: 33722477
Drug: Conventional follitropin
Normalized name: FOLLITROPIN
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Conventional follitropin beta dosing (150 IU/day for the first 5 days, with potential subsequent dose adjustments)
Study: 33790400
Drug: Isometric exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isometric exercises (maximum clenching for 10 seconds, repeated five times, twice daily for 4 weeks)
Study: 33790400
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (tapping teeth at arbitrary speed for 10 seconds, repeated five times, twice daily for 4 weeks)
Study: 33491582
Drug: Paracetamol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1.5 g)
Study: 33491582
Drug: Tramadol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (100 mg) and Paracetamol (1.5 g)
Study: 36199120
Drug: Problem-solving therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving therapy (PST) plus BEACON smartphone application
Study: 36199120
Drug: Problem-solving therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving therapy (PST) alone
Study: 34759989
Drug: Apple syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apple syrup (Malus domestica), administered three times a day along with antiemetic treatment and chemotherapy
Study: 33144461
Drug: Negative Pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative Pressure Wound Therapy (NPWT) using the PICO™ device
Study: 34252252
Drug: Tacrolimus 0.1%
Normalized name: TACROLIMUS 0.1% OINT,TOP
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus 0.1% ointment (T group)
Study: 32205226
Drug: Lusutrombopag (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lusutrombopag (3 mg) daily for 7 days before the invasive procedure
Study: 34581270
Drug: Tamoxifen 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 300 mg/day
Study: 34334142
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care intervention by a pharmacist trained in motivational interviewing
Study: 35878584
Drug: Antidepressants treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants treatment (specifics not provided)
Study: 32632450
Drug: EOC: 44.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: EOC: 44.1 mg/kg CS
Study: 32632450
Drug: MON: 50.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: MON: 50.8 mg/kg CS
Study: 35501519
Drug: 755-nm picosecond
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 755-nm picosecond alexandrite laser with topical tranexamic acid (TTA) combination therapy
Study: 33482902
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of intravenous hAF (in the last 6 patients)
Study: 32440816
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids at a daily dose of 1000 mg for 30 days
Study: 34006508
Drug: Subretinal AAV8.CNGA3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subretinal AAV8.CNGA3 gene therapy
Study: 34030027
Drug: Buprenorphine (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (administered two hours before assessment)
Study: 35610642
Drug: Intra-articular hyaluronan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular hyaluronan (HA) injections
Study: 34404045
Drug: Herbal oil
Normalized name: MENTHOL 3.5 g in 100 mL TOPICAL OIL [Double Prawn Brand Herbal Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal oil cream
Study: 36075246
Drug: Evolocumab 420
Normalized name: evolocumab 420 in 3.5 ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 420 mg monthly with background statins with or without ezetimibe for 80 weeks
Study: 34810387
Drug: Antioxidant therapy
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant therapy containing natural lycopene with green tea extract
Study: 36099282
Drug: Personalized biological
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized biological feedback related to physical activity behaviors
Study: 34202314
Drug: Duloxetine 30
Normalized name: duloxetine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 30 mg once a day
Study: 34495340
Drug: Extended-Release Buprenorphine
Normalized name: Buprenorphine Extended-Release Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-Release Buprenorphine (XRB)
Study: 34495340
Drug: Daily Sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Sublingual Buprenorphine-Naloxone (SLB)
Study: 33283485
Drug: AKCEA‐TTR‐LRx 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKCEA‐TTR‐LRx 45 mg
Study: 33283485
Drug: AKCEA‐TTR‐LRx 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKCEA‐TTR‐LRx 60 mg
Study: 33283485
Drug: AKCEA‐TTR‐LRx 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKCEA‐TTR‐LRx 90 mg
Study: 33283485
Drug: AKCEA‐TTR‐LRx 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKCEA‐TTR‐LRx 120 mg (single dose)
Study: 35123014
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with different illumination times
Study: 35426781
Drug: i-gel® (supraglottic
Approvals — FDA: no, EMA: no, PMDA: no
Description: i-gel® (supraglottic airway)
Study: 39222649
Drug: Gefapixant 45
Normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Gefapixant 45 mg twice daily
Study: 33301646
Drug: POLST DNR/Limited
Approvals — FDA: no, EMA: no, PMDA: no
Description: POLST DNR/Limited Treatment
Study: 33775313
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of BEV and Stupp protocol
Study: 33798499
Drug: Meningococcal conjugate
Normalized name: meningococcal conjugate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal conjugate control (MenACWY) vaccine
Study: 32869124
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g TXA
Study: 32869124
Drug: 2.0 g
Normalized name: Fifty50 2.0 Glucose Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g TXA
Study: 32869124
Drug: 3.0 g
Normalized name: LACTIC ACID 23.0 g in 1 L TOPICAL SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 g TXA
Study: 32869124
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g TXA
Study: 34599466
Drug: Bacillus coagulans
Normalized name: Bacillus coagulans
DrugBank: Bacillus coagulans (DB19246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus coagulans Unique IS2 with lactulose (15 mL suspension of probiotic (B. coagulans Unique IS2, 2 × 10^9 spores) with lactulose (10 g))
Study: 32452846
Drug: Intravenous P2Y12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous P2Y12 inhibitor cangrelor
Study: 36239434
Drug: No-cost cryotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-cost cryotherapy treatment
Study: 36239434
Drug: Work, household
Approvals — FDA: no, EMA: no, PMDA: no
Description: Work, household obligations, and fear of treatment
Study: 35253581
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (SCI) - 1cc triamhexal (n=25)
Study: 32667287
Drug: Argatroban treatment
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Argatroban treatment for 7 days
Study: 36137674
Drug: Drug-coated balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-coated balloon (DCB) treatment
Study: 32989795
Drug: Doravirine 100
Normalized name: doravirine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doravirine 100 mg twice daily coadministered with rifabutin
Study: 32989795
Drug: Doravirine 100
Normalized name: doravirine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doravirine 100 mg once daily
Study: 32086985
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of an encecalin standardized extract of Ageratina pichinchensis for 6 months
Study: 34456283
Drug: Local application
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local application of bisphosphonate gel
Study: 34456283
Drug: Local application
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local application of recombinant human bone morphogenic protein 2 gel
Study: 34456283
Drug: Local application
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local application of a mixed formula of both gels
Study: 34456283
Drug: Implant insertion
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant insertion without application of any medication (Control)
Study: 32057490
Drug: BPPV diagnosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPPV diagnosis and treatment system
Study: 35512719
Drug: Chimeric haemagglutinin
Normalized name: Haemagglutinin-strain B
DrugBank: Haemagglutinin-strain B (DB15482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric haemagglutinin influenza split‐virion vaccines adjuvanted with AS01
Study: 35512719
Drug: Chimeric haemagglutinin
Normalized name: Haemagglutinin-strain B
DrugBank: Haemagglutinin-strain B (DB15482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric haemagglutinin influenza split‐virion vaccines adjuvanted with AS03
Study: 35512719
Drug: Chimeric haemagglutinin
Normalized name: Haemagglutinin-strain B
DrugBank: Haemagglutinin-strain B (DB15482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric haemagglutinin influenza split‐virion vaccines non‐adjuvanted
Study: 35703882
Drug: β-blockers (bisoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-blockers (bisoprolol 10 mg or atenolol 100 mg)
Study: 34180428
Drug: Sham Mirror
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham Mirror Therapy (C)
Study: 33040810
Drug: Floium ginkgo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Floium ginkgo extract and tertram ethypyrazine sodium chloride injection
Study: 33040810
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment measures
Study: 32011301
Drug: Amiodarone at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone at a maintenance dose for one year (n=60)
Study: 32464043
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of surgical and systemic therapies
Study: 35984496
Drug: Concurrent bilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent bilateral anodal tDCS of primary motor cortex and cerebellum (2 mA, 20 min)
Study: 33879680
Drug: Biqi capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biqi capsule combined with diclofenac sodium sustained release tablets
Study: 33879680
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium sustained-release tablets alone
Study: 32012411
Drug: Pembrolizumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab monotherapy 200 mg every 3 weeks for 2 years or until progression, death, unacceptable toxicity or consent withdrawal
Study: 34971040
Drug: Tablet-based training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based training
Study: 32266572
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all three techniques (NIR, blue dye, RC)
Study: 34401422
Drug: PA-TXA (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA-TXA (15 mg/kg)
Study: 34401422
Drug: IA-TXA (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA-TXA (2 g)
Study: 34401422
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no TXA injection)
Study: 34332584
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg daily for 24 weeks
Study: 35202432
Drug: Probiotics supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics supplements orally twice a day for 3 months
Study: 35202432
Drug: Placebo supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplements orally twice a day for 3 months
Study: 35644993
Drug: Exercise-based cardiovascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise-based cardiovascular rehabilitation program (CR) with 3 weekly exercise sessions for 6 months
Study: 35895508
Drug: Casirivimab and
Normalized name: Casirivimab and Imdevimab
DrugBank: Casirivimab (DB15941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Casirivimab and Imdevimab (CAS + IMD) 2.4 g
Study: 35895508
Drug: Casirivimab and
Normalized name: Casirivimab and Imdevimab
DrugBank: Casirivimab (DB15941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Casirivimab and Imdevimab (CAS + IMD) 8.0 g
Study: 616191718
Drug: Complex decongestive
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex decongestive therapy (CDT) for 2 weeks
Study: 33306110
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplements
Study: 35775723
Drug: GLP-1 receptor
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 receptor blocker exendin[9-39] (Ex-9)
Study: 35775723
Drug: DPP4 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPP4 inhibitor (sitagliptin)
Study: 34325975
Drug: Hydrocortisone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (200 mg continuous infusion for 7 days)
Study: 33740568
Drug: IV paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV paracetamol 1000 mg
Study: 32457366
Drug: Water spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water spray (WS) applied every 15 minutes during exercise
Study: 33755168
Drug: High-dose amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose amoxicillin (875 mg) plus clavulanate (125 mg) twice a day for 7 days
Study: 33755168
Drug: Standard-dose amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose amoxicillin (875 mg) plus clavulanate (125 mg) plus placebo, twice a day for 7 days
Study: 33755168
Drug: High-dose amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose amoxicillin (875 mg) plus clavulanate (125 mg)
Study: 33755168
Drug: Standard-dose amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose amoxicillin (875 mg) plus clavulanate (125 mg) plus placebo
Study: 34256031
Drug: Tezepelumab 210
Normalized name: TEZEPELUMAB 210 mg in 1.9 mL SUBCUTANEOUS INJECTION, SOLUTION [TEZSPIRE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezepelumab 210 mg administered subcutaneously every 4 weeks for 28 weeks (extended to 52 weeks if needed)
Study: 32359153
Drug: USDA‐LB (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: USDA‐LB (150 g/d lean beef as an isocaloric replacement for carbohydrate)
Study: 35953719
Drug: Obicetrapib 5
Normalized name: Obicetrapib
DrugBank: Obicetrapib (DB14890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obicetrapib 5 mg
Study: 38705341
Drug: Obicetrapib 10
Normalized name: Obicetrapib
DrugBank: Obicetrapib (DB14890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obicetrapib 10 mg
Study: 32051386
Drug: Post-DOAC hsCRP
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-DOAC hsCRP >0.100 mg/dL
Study: 34212138
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and topical Tranexamic Acid (TXA)
Study: 33788216
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D status in winter (25(OH)D concentration 26.9 nmol/L)
Study: 33788216
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D status in summer (25(OH)D concentration 43.4 nmol/L)
Study: 34979503
Drug: Boron-based gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boron-based gel containing 3% sodium pentaborate pentahydrate
Study: 34979503
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel with no chemical substance
Study: 33892722
Drug: Inofolic (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inofolic (4 g myo‐inositol + 400 μg folic acid)
Study: 33892722
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (400 μg)
Study: 35114340
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg/day for 90 days
Study: 35818296
Drug: oVRcome app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oVRcome app (self-guided virtual reality exposure and cognitive behaviour therapy)
Study: 34417781
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (n = 45)
Study: 34417781
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment (control group, n = 46)
Study: 34632865
Drug: Virtual game
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Virtual game training using the SeeMe virtual game system (12 sessions of 30 minutes bi-weekly)
Study: 32844575
Drug: Intradialytic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradialytic group laughter therapy (30-minute session once weekly for 8 weeks)
Study: 32189678
Drug: Cold chain
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold chain equipment (CCEs) assessment using WHO‐UNICEF Effective Vaccine Management (EVM) tool
Study: 32189678
Drug: Electrical vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical vaccine storage equipment
Study: 32189678
Drug: Ice packs
Normalized name: Camphor Ice Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice packs preparation and storage capacity
Study: 35526121
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) risedronate taken fasted (group A)
Study: 35526121
Drug: Gastro-resistant (GR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastro-resistant (GR) formulation 1 taken fasted (group B)
Study: 35526121
Drug: Gastro-resistant (GR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastro-resistant (GR) formulation 2 taken fasted (group C)
Study: 35526121
Drug: Gastro-resistant (GR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastro-resistant (GR) formulation 3 taken fasted (group D)
Study: 35526121
Drug: Gastro-resistant (GR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastro-resistant (GR) formulation 4 taken fasted (group E)
Study: 35526121
Drug: Gastro-resistant (GR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastro-resistant (GR) formulation 1 taken with food (group F)
Study: 35526121
Drug: Gastro-resistant (GR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastro-resistant (GR) formulation 2 taken with food (group G)
Study: 35526121
Drug: Gastro-resistant (GR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastro-resistant (GR) formulation 3 taken with food (group H)
Study: 35526121
Drug: Gastro-resistant (GR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastro-resistant (GR) formulation 4 taken with food (group I)
Study: 35202553
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg STM
Study: 35202553
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg STM
Study: 33736601
Drug: Warm solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm solution containing 30 ml 5% sodium bicarbonate solution and 15 ml reformulated simethicone emulsion